article thumbnail

MHRA Chief Executive to step down

European Pharmaceutical Review

The Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA), Dame June Raine, will step down in the Autumn following five years in the role. Previous roles The MHRA highlighted Dame June Raine has been Chief Executive Officer of the MHRA since August 2019.

article thumbnail

Pharma Injecting Life into Digital Health Amidst Funding Downturn

MedCity News

The evolution to the new normal Given the evolving climate, Rock Health provided the apt advice as: “rather than aiming to ‘disrupt’ the entire healthcare system, focus is best placed on applying practiced skill sets to top healthcare and research problems.”

Pharma 92
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Women in Alabama could face prosecution over use of abortion pills

pharmaphorum

The Attorney General of Alabama has threatened to use an obscure law passed in 2006 to prosecute women who terminate a pregnancy using pharmacological means, shortly after the FDA made access to the drugs easier.

article thumbnail

Developing new treatment regimens for HIV

European Pharmaceutical Review

About the author Sherene Min, MD, MPH, is Vice President of Global Clinical Development at ViiV Healthcare , a role she assumed in October 2019. With therapeutic expertise in HIV, hepatology and rare diseases, Sherene has additional expertise in clinical pharmacology and drug safety.

article thumbnail

Why R&D innovation holds the key to greater patient impact

European Pharmaceutical Review

In 2019, the pharmaceutical industry spent $83 billion on R&D, which is about 10 times what the industry spent per year in the 1980s, 4 yet the average duration to develop a new medicine is still around 10-15 years. About the authors Dr Nils Eckardt joined BeiGene in February 2019 as Vice President, Medical Affairs, Europe.

article thumbnail

What to watch in the life sciences in 2024

Clarivate

Here are a few trends in life sciences and healthcare our analysts are keeping an eye on – and what they expect to see in 2024: Move over, oncology – metabolic drugs are the new hotness: The successful launches of Novo Nordisk’s Wegovy® and Eli Lilly’s Mounjaro® represent a revolutionary pharmacological breakthrough of rare proportions.

Pharma 111
article thumbnail

Recurrent drug shortages signal onerous outlook for cardiovascular care

Pharmaceutical Technology

Cardiovascular medicines were ranked as the sixth most affected drug class by shortages, as per a 2019 European Association of Hospital Pharmacists (EAHP) survey, says the organisation’s director of finance, Nenad Miljkovi?. To me, even [if] a shortage has resolved, it is only a matter of time until it happens again,” he explains.

Medicine 111